Drug profile · INN
droperidol
DROPERIDOL
droperidol (DROPERIDOL) is a d2-like dopamine receptor antagonist. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
Drug details — droperidol
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
droperidol (DROPERIDOL) is a d2-like dopamine receptor antagonist. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
D2-like dopamine receptor antagonist
Primary target: D2-like dopamine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is droperidol?
droperidol (DROPERIDOL) is a d2-like dopamine receptor antagonist. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: injection. Current US regulatory status: approved.
What is the brand name for droperidol?
DROPERIDOL is a marketed brand name for droperidol. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of droperidol?
droperidol has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.